Stay updated with breaking news from Collaborative Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
An international group of physicians has issued a list of 31 treatment recommendations for patients diagnosed with early-onset colorectal cancer (before 50 years of age).
The FDA has accepted the sNDA for empagliflozin to reduce the risk of kidney disease progression and CV death in adults with chronic kidney disease.
Data confirms the 10-year screening colonoscopy interval is safe for average-risk adults and can be extended in some subgroups, supporting the possibility of personalized, risk-adapted CRC screening.
The FDA has accepted the sNDA for empagliflozin to reduce the risk of kidney disease progression and CV death in adults with chronic kidney disease.